Molecular and biological functions of resveratrol in psychiatric disorders: a review of recent evidence

Cell & Bioscience

Table 3 Studies that investigated the therapeutic effects of resveratrol on ASD

Disease	Dose of resveratrol	Model	Findings	Publish year	Ref
Animal stusies
Valproic acid-induced ASD	3.6 mg/kg	In vivo	Improved social behavior	2014	[121]
Oxytocin receptor gene knockout (Oxtr-KO) and valproic acid-induced ASD	30 mg/kg	In vivo	Upregulated Sirt1 and Egr3, improved social behaviors	2020	[123]
BTBR-induced ASD	20 and 40 mg/kg	In vivo	Decreased levels CD4⁺TLR2⁺, CD4⁺TLR3⁺, CD4⁺TLR4⁺ CD4⁺NF-κB⁺, and CD4⁺iNOS⁺ in spleen cells, decreased TLR2, TLR3, TLR4, NF-κB, iNOS, and COX-2 in the brain tissue	2018	[129]
Valproic acid-induced ASD	3.6 mg/kg	In vivo	Prevented ASD-like behaviors	2018	[131]
B6- and BTBR-induced ASD	20 and 40 mg/kg	In vivo	upregulated Foxp3⁺, reduced T-bet⁺, GATA-3⁺, and IL-17A⁺ expressions and protein levels in CD4⁺ cells, spleen, and brain tissues	2017	[130]
BTBR-induced ASD	20 and 40 mg/kg	In vivo	Decreased levels of IL-6⁺, TNF-α⁺, IFN-γ⁺, and STAT3⁺ in CD4⁺ spleen cells and brain tissue	2017	[132]
Decreased ERβ- induced ASD	20 mg/kg	In vivo	activated ERβ, decreased oxidative stress, mitochondrial dysfunction, and lipid metabolism in the brain	2018	[124]
BTBR-induced ASD	20 and 40 mg/kg	In vivo	Decreased CCR and CXCR expression in CD4⁺ T cells in spleen and brain tissues	2016	[133]
ASD	5, 10 and 15 mg/kg	In vivo	Inhibited oxidative stress, mitochondrial dysfunction, MMP-9 and TNF-α expression	2017	[10]
Human studies
ASD	250 mg twice per day	Human	Decreased hyperactivity/non-compliance score	2020	[122]

ISSN: 2045-3701